Topic collections
Patients: 426 adults with DSM-IV generalised anxiety disorder (GAD; diagnosed using the Mini-International Neuropsychiatric Interview) with predominantly symptoms of anxiety rather than depression (Covi Anxiety Scale score >9 and Raskin Depression Scale score (7) and Hamilton Rating Scale for Anxiety (HAM-A) score >20. Main exclusions: current Axis I disorders (except simple phobia, somatisation disorder, dysthymia, or depression not otherwise specified); antisocial, borderline, or avoidant personality disorder, recent alcohol or substance use disorder; risk of suicide; ongoing psychodynamic or cognitive-behavioural psychotherapy; or clinically relevant medical comorbidity.
Intervention: Pregabalin (400 mg/day or 600 mg/day), venlafaxine (75 mg/day) or placebo for 6 weeks.
Outcomes: Change in symptoms of generalised anxiety disorder (change in HAM-A total score from baseline).
Patient follow up: 76% of randomised participants completed 6 weeks' treatment; 99% were included in last observation carried forward analyses.
MAIN RESULTS
Pregabalin (both 400 mg and 600 mg daily doses) and venlafaxine both significantly reduced symptoms of GAD compared with placebo at six weeks (reduction in HAM-A score: 14.7 with pregabalin 400 mg/day v 14.1 with pregabalin 600 mg/day v 14.1 with venlafaxine 75 mg/day v 11.6 with placebo; p = 0.008 for pregabalin 400 mg/day v placebo, p = 0.03 for pregabalin 600 mg/day v placebo, and p = 0.03 for venlafaxine 75 mg/day v placebo). Venlafaxine significantly increased withdrawals due to adverse events compared with pregabalin 400 mg/day, but no other statistical comparisons were reported (withdrawals: 6% with pregabalin 400 mg/day v 14% with pregabalin 600 mg/day v 20% with venlafaxine 75 mg/day v 10% with placebo; p,0.01 for venlafaxine v pregabalin 400 mg/day). 
CONCLUSIONS

Commentary
T his paper is one of the few studies to compare active medications in the treatment of generalised anxiety disorder (GAD). There is growing consensus that GAD is an independent and disabling psychiatric disorder that deserves early diagnosis and treatment. 1 2 This work has given impetus to treatment studies, which have in turn demonstrated that medication can play a useful role in treating symptoms, and perhaps even in preventing subsequent depression. 3 4 Comparative studies may be particularly informative. An influential early study of diazepam, imipramine, and trazodone demonstrated that diazepam had an earlier onset and was more effective for somatic symptoms at week 2, but that all agents had similar efficacy at endpoint. 5 Studies comparing different antidepressants in GAD have suggested that there may be advantages for certain agents in terms of efficacy or tolerability. 6 7 The current study compares two doses of pregabalin (400 mg/d) with venlafaxine (75 mg/d) and placebo in a six-week study in primary care and psychiatric centres. Pregabalin is a newly introduced agent, characterised by high-affinity binding to the a 2 -d subunit protein of voltage-gated calcium channels, and is effective in neuropathic pain and GAD. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) with known efficacy in GAD.
All active arms resulted in greater decrease in the HAM-A at endpoint compared with placebo. At week 1, both doses of pregabalin were significantly more effective than venlafaxine in decreasing HAM-A total, and this advantage was also apparent at this timepoint in the HAM-A psychic factor score (for pregablin 600 mg/d) and the HAM-A somatic factor score (both doses). Discontinuation rates due to adverse events were greatest in the venlafaxine group.
These data are useful in suggesting that pregabalin may have advantages in terms of earlier onset-of-action, efficacy for both psychic and somatic GAD symptoms, and tolerability. Additional work is needed to determine whether these promising data hold true over the longer term (12 weeks, and more), and whether the many patients with GADdepression comorbidity also respond to this agent.
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